

Supplementary Table 2. Subgroup analysis of mean and delta glycated hemoglobin in the tele-prescription and non-tele-prescription groups according to complication

Variable	Tele-prescription			Non-tele-prescription			p value
	Period 1	Period 2	ΔHbA1c, %	Period 1	Period 2	ΔHbA1c, %	
Coronary artery disease	53			46			
HbA1c, %	7.61 ± 1.25	7.77 ± 1.23	0.168	7.44 ± 1.08	7.55 ± 1.43	0.115	0.794
Without coronary artery disease	250			256			
HbA1c, %	7.20 ± 1.09	7.40 ± 1.24	0.198	7.21 ± 1.18	7.23 ± 1.20	0.025	0.015
CVA	42			24			
HbA1c, %	7.30 ± 1.06	7.50 ± 1.24	0.200	7.18 ± 1.11	7.75 ± 1.36	0.571	0.102
Without CVA	261			278			
HbA1c, %	7.27 ± 1.14	7.46 ± 1.25	0.191	7.25 ± 1.17	7.24 ± 1.23	-0.007	0.005
Diabetic neuropathy	43			27			
HbA1c, %	7.84 ± 1.27	8.05 ± 1.56	0.207	7.60 ± 1.17	7.57 ± 1.35	-0.030	0.310
Without diabetic neuropathy	260			275			
HbA1c, %	7.18 ± 1.08	7.37 ± 1.16	0.190	7.21 ± 1.16	7.25 ± 1.23	0.046	0.037

Values are presented as number or mean ± standard deviation. Data were analyzed using an independent *t* test. ΔHbA1c, glycated hemoglobin concentration; HbA1c, glycated hemoglobin; CVA, cerebrovascular accident.